Date: 2014-05-21
Type of information: Termination of an agreement
Compound: WX-554, WX-037 and for three preclinical antibody programmes
Company: Wilex (Germany) UCB (Belgium)
Therapeutic area: Cancer - Oncology
Type agreement: R&D licensing
Action mechanism:
Disease:
Details: * On May 21, 2014, Wilex announced that due to the strategic re-alignment implemented at WILEX AG, the collaboration agreement for the clinical product candidates WX-554 and WX-037 and for three preclinical antibody programmes has been terminated by mutual agreement. Wilex will return all rights granted and will transfer all intellectual property, data and documents generated in connection with the programmes to UCB. Furthermore an agreement regarding an antibody programme for non-oncology indications signed last year has been terminated. Wilex will receive a final payment for reimbursement of R&D expenses. UCB has agreed to waive repayment of the €2.5 million shareholder loan granted in December 2010 on completion of the transfer. This does not affect UCB\'s role as a shareholder of Wilex.
Financial terms:
Latest news:
